SARS-CoV-2 Clinical Trial
Official title:
Efficacy and Safety of Hydroxychloroquine in Primary Prophylaxis of SARS-CoV-2 Infection in Healthcare Workers at Risk of Exposure: Randomised Control Trial
Healthcare personnel are at an increased risk of exposure to SARS-CoV-2 infection while handling such patients. Currently, there is no treatment available for SARS-CoV-2 and stringent preventive measures are advised to avoid or minimize risk of exposure to healthcare workers. There are in vitro studies available which show inhibition of corona virus by hydroxychloroquine, a widely-used agent against malaria and certain autoimmune conditions and of low-cost and limited toxicity. However, evidence regarding its effects in patients is limited. We plan to conduct a randomized controlled trial to evaluate the safety and potential prophylactic efficacy of hydroxychloroquine in preventing secondary SARS-CoV-2 infection among healthcare workers at high-risk of exposure while managing such patients.
Status | Not yet recruiting |
Enrollment | 374 |
Est. completion date | October 15, 2020 |
Est. primary completion date | June 30, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility |
Inclusion Criteria: - Adult healthcare workers all genders = 18 to = 60 years of age upon study consent. - Healthcare workers (doctors and nurses) at Services hospital, Lahore considered work at high-risk of SARS-CoV-2 exposure (defined below): - Healthcare workers in Corona triage areas. - Healthcare workers in Corona Isolation Units. - Healthcare workers in Corona ICUs. - Healthcare workers in general medical wards. - Healthcare workers in general surgical wards. - Healthcare workers in other units not directly dealing with suspected Corona patients e.g. Endocrinology department - Afebrile with no constitutional symptoms. - No household contact with confirmed active SARS-CoV-2 infection in the last 3 weeks. - Negative PCR at visit 0. - Willing and able to comply with scheduled visits, treatment plan, and other study procedures. - Willing to not take any other medicines especially fluoroquinolones and macrolides for the duration of study. - Signed informed consent, demonstrating that the subject understands the interventions required for the study and the purpose of the study. Exclusion Criteria: - Participation in other investigational clinical trials for the treatment or prevention of SARS-CoV-2 infection within 30days. - Subjects unwilling to practice at least one highly effective method of birth control for the duration of the study. - Having a prior history of blood disorders such as aplastic anemia, agranulocytosis, leukopenia, or thrombocytopenia or prior history of glucose-6-phosphate dehydrogenase (G-6-PD) deficiency. - Having H/O skin disorders e.g. dermatitis, psoriasis or porphyria. - Taking any of the following medication: - Anti-arrythmic agents including digoxin. - GI drugs including antacids, proton-pump inhibitors, cimetidine. - Anti-cancer treatment including methotrexate, cyclosporin. - Anti-diabetic agents including insulin. - Corticosteroids. - Drugs causing QT interval prolongation especially antidepressants, anti-epileptics and macrolides. - Drugs affecting electrolyte balance including diuretics, laxatives. - Drug allergies: 4-Aminoquinolines. - Pre-existing retinopathy/maculopathy of the eye. - Known chronic liver disease or cirrhosis, including hepatitis B and/or untreated hepatitis. - Previous history of severe hypoglycaemia. - Known case of renal disease. - Untreated or uncontrolled active bacterial, fungal infection. - Known or suspected active drug or alcohol abuse. - Women who are pregnant or breastfeeding. - Known hypersensitivity to any component of the study drug. - A known history of prolonged QT syndrome or history of additional risk factors for arrythmias (e.g., heart failure, family history of Long QT Syndrome). - Known H/O respiratory disorders e.g. asthma, chronic obstructive pulmonary disease. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Services Institute of Medical Sciences, Pakistan |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Prevention of SARS-CoV-2 as determined by negative RT-PCR at the end of 12 week study period | Negative RT-PCR for SARS-CoV-2 both at baseline and at end of 12 weeks in experimental arm | From date of randomization until study completion 12 weeks after treatment initiation | |
Primary | Safety as determined by presence or absence of any adverse event related with hydroxychloroquine treatment | To assess the presence or absence of side effects from HCQ treatment. | From date of randomization until the appearance of symptoms or study completion 12 weeks after treatment initiation | |
Secondary | Confirmed SARS-CoV-2 infection based on symptoms and confirmed by RT-PCR | Symptomatic infection by SARS-CoV-2 defined as cough, dyspnea, fever, myalgia, arthralgia or rhinorrhea. | From date of randomization until the appearance of symptoms or study completion 12 weeks after treatment initiation | |
Secondary | Clinical disease severity in confirmed SARS-CoV-2 participants | Disease severity including i) asymptomatic. ii) Mild symptoms but ambulatory. iii) Moderate symptoms requiring hospitalisation. iv) severe symptoms requiring ICU care and oxygen. v) Severe symptoms requiring assisted mechanical ventilation. vi) Death. | From date of randomization until the appearance of symptoms or study completion 12 weeks after treatment initiation | |
Secondary | Incidence of any acute respiratory infection | Symptomatic non-COVID viral infection (any other acute respiratory illness with fever but without evidence of epidemiological risk factors such as close contact with SARS-CoV-2 positive patient or travel to or residence in high-risk area). | From date of randomization until the appearance of symptoms or study completion 12 weeks after treatment initiation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT04527471 -
Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19
|
Phase 2 | |
Recruiting |
NCT05584202 -
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants
|
Phase 2 | |
Completed |
NCT04579549 -
Repeat Testing for SARS-CoV-2
|
N/A | |
Active, not recruiting |
NCT05547243 -
A Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants in China
|
N/A | |
Recruiting |
NCT04613310 -
PCR and Rapid Diagnostic Test on Saliva and Nasopharyngeal Swabs for the Detection of SARS-CoV-2 (COVID-19)
|
N/A | |
Recruiting |
NCT04747574 -
Evaluation of the Safety of CD24-Exosomes in Patients With COVID-19 Infection
|
Phase 1 | |
Terminated |
NCT04447404 -
DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury
|
Phase 2 | |
Completed |
NCT04515147 -
A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
|
Phase 2 | |
Withdrawn |
NCT04388709 -
Interferon Lambda Therapy for COVID-19
|
Phase 2 | |
Active, not recruiting |
NCT05550142 -
A Preliminary Exploratory Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in China
|
N/A | |
Completed |
NCT04620798 -
Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students
|
N/A | |
Active, not recruiting |
NCT05547256 -
A Preliminary Exploratory Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants Aged 18 Years and Over in China
|
N/A | |
Completed |
NCT04452604 -
Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19
|
||
Completed |
NCT04561102 -
Evaluation of the COVIDSeq Test in Nasal Swab and Saliva From a COVID-19 Asymptomatic Population
|
||
Completed |
NCT05366322 -
A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults
|
||
Completed |
NCT04526769 -
Detecting SARS-CoV-2 in Tears
|
||
Terminated |
NCT04958304 -
Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study
|
||
Completed |
NCT04690413 -
NOWDx Test for the Detection of Antibodies to COVID-19
|
N/A |